Pre-eclampsia
The benefit of the Elecsys® sFlt-1/PlGF quotient for healthcare practitioner and laboratory
Information for laboratory specialists
Avoid unnecessary hospitalizations with the prediction algorithm of Elecsys® sFlt-1/PlGF
Benefits for all involved
Diagnosis of pre-eclampsia is complex
It is the cause of 15% of premature births1 and of 42% of maternal decease during childbirth2.
Pre-eclampsia management during the entire pregnancy with Roche Elecsys® assays
Risk assessment in the 1st trimester with the Elecsys® PlGF assay
Data required by the FMF algorithm:
- Maternal history data
- Maternal mean arterial pressure (MAP)
Mean uterine artery pulsatility index (UTPI)
Biomarker PlGF from serum
sFlt-1/PlGF ratio: diagnosis and prediction in the 2nd/3rd trimester
- Clinically validated cut-off values
- Support in rule-out, diagnosis and prediction
- Reduction of health care costs
Important criteria for sFlt-1/PlGF test selection
Elecsys® sFlt-1/PlGF from Roche...
- ... is recommended by the NICE Institute because of the strong clinical evidence it provides
- ... are the first available and approved automated diagnostic tests for fast and easy assessment in a clinical context 17,18
- ... are a reliable tool to identify the patients that are at high risk to develop pre-eclampsia requiring a closer monitoring and to confidently send home patients that are not likely to develop the disease17-20
- ... support the healthcare practitioner in making an informed, early and precise diagnosis of pre-eclampsia, which can lead to effective clinical management and improved outcome for both mother and child17-20
Elecsys® sFlt-1 & PlGF
The use of the Elecsys® sFlt-1/PlGF ratio is a reliable tool to identify patients at high risk of developing pre-eclampsia who require closer monitoring.
sFlt-1/PlGF ratio: guidelines and recommendations
Multiple guidelines recommend the use of Elecsys® sFlt-1/PlGF for screening and aid in diagnosis of pre-eclampsia (ISUOG, FIGO, ISSHP, NICE, ...)
Roche Women's Health Portfolio
Roche Diagnostics is committed to women’s health at every stage of her life and to giving healthcare providers the confidence to safeguard the moments that matter most. Our innovative solutions in women’s health give physicians the ability to provide the right treatment at the right time, offering a confidence that only Roche Diagnostics can deliver.
Sources
1. Tency l. et al. Perinatal referral in Belgium. FOD, 2007
2. Verlohren S. et al. (2010). Am J. Obstet Gynecol, 202 (161): e1-11
3. Milne et al. (2009) BMJ, 339:b3129
4. Health Belgium, 2019
5. O’Gorman et al. (2016). Am J. Obstet Gynecol, 214: 103.e1-12
6. O’Gorman N et al. (2017). Ultrasound Obstet Gynecol, 49: 756–760
7. Rolnik et al. (2017). N Engl J Med, 377(7):613-622
8. Poon L.C. et al, Int J Gynecol Obstet 2019;145(Suppl.1): 1-33
9. Zeisler H. et al. (2016). N Engl J Med, 374: 13-22
10. Verlohren et al. (2014). Hypertension, 63: 346-352
11. Lanssens, D. et al. (2017). JMIR mHealth and uHealth, 5(3), e25
12. KCE Report 232Cs. Caring for mothers and newborns after uncomplicated
delivery: towards integrated postnatal care
13. Statbel (2019, February 26). Feto-infant mortality
Retrieved March 12, 2019, from: https://statbel.fgov.be/en/themes/
population/feto-infant-mortality
14. Information received by request to FPS Health
15. Wright, D. et al. (2018). Am J Obstet Gynecol, 218(6), 612-e1
16. Terugbetalingsdossier Elecsys ® sFlt-1-PlGF immunoassay ratio. Submitted to RIZIV/INAMI November 2019
17. Hund, M., et al. (2014). BMC Pregnancy and Childbirth 14, 324
18. Zeisler, H., et al. (2016). N Engl J Med 374(1), 13-22
19. Hund, M., et al. (2015). Hypertens Pregnancy 34(1), 102-115
20. Klein, E., et al. (2014). PLoS ONE 11(5), e0156013
Information for Healthcare professionals
Avoid unnecessary hospitalizations with the prediction algorithm of Elecsys® sFlt-1/PlGF
Benefits for all involved
Diagnosis of pre-eclampsia is complex
It is the cause of 15% of premature births1 and of 42% of maternal decease during childbirth2.
Pre-eclampsia management during the entire pregnancy with Roche Elecsys® assays
Risk assessment in the 1st trimester with the PlGF biomarker
Risk assessment for pre-eclampsia in the 1st trimester helps to identify high-risk patients.
sFlt-1/PlGF ratio: diagnosis and prediction in the 2nd/3rd trimester
- Clinically validated cut-off values
- Support in rule-out, diagnosis and prediction
- Reduction of health care costs
sFlt-1/PlGF ratio: Improved screening of potential PE patients
- Confident decisions regarding treatment and disease management
- Reassure patients and avoid unnecessary stress and hospitalisation
sFlt-1/PlGF ratio: guidelines and recommendations
Multiple guidelines recommend the use of Elecsys® sFlt-1/PlGF for screening and aid in diagnosis of pre-eclampsia (ISUOG, FIGO, ISSHP, NICE, ...)
Roche Women's Health Portfolio
Roche Diagnostics is committed to women’s health at every stage of her life and to giving healthcare providers the confidence to safeguard the moments that matter most. Our innovative solutions in women’s health give physicians the ability to provide the right treatment at the right time, offering a confidence that only Roche Diagnostics can deliver.
Sources
1. Tency l. et al. Perinatal referral in Belgium. FOD, 2007
2. Verlohren S. et al. (2010). Am J. Obstet Gynecol, 202 (161): e1-11
3. Milne et al. (2009) BMJ, 339:b3129
4. Health Belgium, 2019
5. O’Gorman et al. (2016). Am J. Obstet Gynecol, 214: 103.e1-12
6. O’Gorman N et al. (2017). Ultrasound Obstet Gynecol, 49: 756–760
7. Rolnik et al. (2017). N Engl J Med, 377(7):613-622
8. Poon L.C. et al, Int J Gynecol Obstet 2019;145(Suppl.1): 1-33
9. Zeisler H. et al. (2016). N Engl J Med, 374: 13-22
10. Verlohren et al. (2014). Hypertension, 63: 346-352
11. Lanssens, D. et al. (2017). JMIR mHealth and uHealth, 5(3), e25
12. KCE Report 232Cs. Caring for mothers and newborns after uncomplicated
delivery: towards integrated postnatal care
13. Statbel (2019, February 26). Feto-infant mortality
Retrieved March 12, 2019, from: https://statbel.fgov.be/en/themes/
population/feto-infant-mortality
14. Information received by request to FPS Health
15. Wright, D. et al. (2018). Am J Obstet Gynecol, 218(6), 612-e1
16. Terugbetalingsdossier Elecsys ® sFlt-1-PlGF immunoassay ratio. Submitted to RIZIV/INAMI November 2019